CNS proteinopathy

Pioneering Gene Therapy for CNS proteinopathy Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis (ALS)

Central nervous system (CNS) proteinopathies, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), are characterized by the misfolding and aggregation of proteins, leading to cellular dysfunction and progressive tissue damage. These debilitating diseases affect millions worldwide, and current treatments largely focus on managing symptoms rather than addressing the underlying cause.

At Canary, we are revolutionizing the treatment of CNS proteinopathies by harnessing the power of gene therapy and targeted antibodies. Our unique approach aims to:

Halt disease progression

We utilize innovative gene therapy techniques to correct the underlying genetic defects that contribute to protein misfolding.

Reduce protein accumulation

We deploy targeted antibodies to selectively remove misfolded proteins, preventing further damage to neurons.

Pioneering RNA Therapy

We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.

Disclaimer: Canary Cure Therapeutics Inc’s website includes future planned care offerings, that are currently in development and are subject to regulatory approval before they are able to be commercialized

Quick Links

Useful Links

Quick Contact